Recent studies of hyperacute HIV infection have revealed that HIV-specific CD8 T cells from individuals who receive ART before viral load peak (Fiebig I and II) have improved survival potential with increased expression of Bcl-2 and CD127 (IL-7R) (27, 28) compared with those who start at late stages of infection. This evidence concerns the gene CD8A and infection.